Author
Muni Kumar Meravath is a seasoned Healthcare Market Research Analyst with over 6 years of experience in the healthc.....
Generic Injectables Market By Product Type, By Indication, By Distribution Channel, and Region Forecast 2019-2030
Generic Injectables Market size was valued at US$ 83.09 billion in 2023 and is Poised to grow at a CAGR of 12.2% from 2024-2030. Generic injectables are bioequivalent to their branded counterparts; they are as safe and effective as innovator compounds. Only after the patent on the branded drug has expired can these medications be created for commercial use. Generic injectables have low R&D costs because the drug molecules are equivalent in branded and generic formulations. Drugmakers can sell generic injectables at low prices because of the minimal upfront R&D costs. According to the USFDA, a single generic competitor can result in price reductions of 30%, whereas five generic competitors can result in price reductions of 85%. Furthermore, generic drugs are approved faster than branded medicines. According to the US Food and Drug Administration (USFDA), 107 first-generation generic pharmaceuticals and 110 complicated generic drugs were approved in 2019, accounting for 11% of all generic drug product approvals.
One thousand fourteen generic medicine applications were granted or tentatively approved by the generic drugs program in 2019. Furthermore, the development of a new chemical entity takes roughly a decade on average, whereas generic injectables are developed in a fraction of that time. As a result, one of the primary drivers encouraging new companies to enter the market and driving the market is the lower cost associated with generic injectables. Manufacturers in the market are preparing for the future by keeping adequate supply chains to avoid any COVID-19-like vulnerabilities. Drug companies such as Zydus Cadila have been seen lowering the price of Remdac, the generic version of Remdesivir. Companies are utilizing government programs and financing schemes given by the BFSI industry to streamline their operations in response to turbulent market conditions. Furthermore, branded injectables' patents are set to expire in the coming years in several countries, presenting a lucrative opportunity for generic injectables manufacturers. Generational injectables businesses target regulated markets and explore other markets to generate funds and build steady revenue streams.
Study Period
2024-2030Base Year
2023CAGR
12.2%Largest Market
North-AmericaFastest Growing Market
Asia-Pacific
As medicine shortages worsen, governments in several countries are promoting the production of generic injectables, which do not have patents. The increasing aging population and the rise in chronic disease cases are two further factors contributing to the growth of generic injectables. Since generic injectables are bioequivalent, generic medications have shorter R&D cycles than their branded counterparts, and these benefits producers by reducing time and contributing to expanding the generic injectable market. The expiration of branded injectable patents and a decrease in the frequency of new launches are two reasons that have aided the expansion of the generic injectable industry. On the other hand, the production of generic injectables is relatively complex. In many underdeveloped nations, the absence of competent labor can be a stumbling block for the generic injectable industry.
Report Benchmarks |
Details |
Report Study Period |
2024-2030 |
Market Size in 2023 |
US$ 83.09 billion |
Market CAGR |
12.2% |
By Product Type |
|
By Indication |
|
By Distribution Channel |
|
By Region |
|
Download Free Sample Report
The generic injectables market size was valued at US$ 83.09 billion in 2023 and is Poised to grow at a CAGR of 12.2% from 2024-2030.
Novartis, AbbVie Inc., Amgen, Inc., AstraZeneca Plc, Baxter International Inc.
North America is the fastest-growing region for the market
1.Executive Summary |
2.Global Generic Injectables Market Introduction |
2.1.Global Generic Injectables Market - Taxonomy |
2.2.Global Generic Injectables Market - Definitions |
2.2.1.Product Type |
2.2.2.Indication |
2.2.3.Distribution Channel |
2.2.4.Region |
3.Global Generic Injectables Market Dynamics |
3.1. Drivers |
3.2. Restraints |
3.3. Opportunities/Unmet Needs of the Market |
3.4. Trends |
3.5. Product Landscape |
3.6. New Product Launches |
3.7. Impact of COVID 19 on Market |
4.Global Generic Injectables Market Analysis, 2019-2023 and Forecast 2024-2030 |
4.1. Market Analysis, 2019-2023 and Forecast, 2024-2030, (Sales Value USD Million) |
4.2. Year-Over-Year (Y-o-Y) Growth Analysis (%) |
4.3. Market Opportunity Analysis |
5.Global Generic Injectables Market By Product Type, 2019-2023 and Forecast 2024-2030 (Sales Value USD Million) |
5.1. Monoclonal Antibodies |
5.1.1. Market Analysis, 2019-2023 and Forecast, 2024-2030, (Sales Value USD Million) |
5.1.2. Year-Over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) |
5.1.3. Market Opportunity Analysis |
5.2. Cytokines |
5.2.1. Market Analysis, 2019-2023 and Forecast, 2024-2030, (Sales Value USD Million) |
5.2.2. Year-Over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) |
5.2.3. Market Opportunity Analysis |
5.3. Insulin |
5.3.1. Market Analysis, 2019-2023 and Forecast, 2024-2030, (Sales Value USD Million) |
5.3.2. Year-Over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) |
5.3.3. Market Opportunity Analysis |
5.4. Vaccines |
5.4.1. Market Analysis, 2019-2023 and Forecast, 2024-2030, (Sales Value USD Million) |
5.4.2. Year-Over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) |
5.4.3. Market Opportunity Analysis |
5.5. Peptide Hormones |
5.5.1. Market Analysis, 2019-2023 and Forecast, 2024-2030, (Sales Value USD Million) |
5.5.2. Year-Over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) |
5.5.3. Market Opportunity Analysis |
5.6. Blood Factors |
5.6.1. Market Analysis, 2019-2023 and Forecast, 2024-2030, (Sales Value USD Million) |
5.6.2. Year-Over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) |
5.6.3. Market Opportunity Analysis |
5.7. Immunoglobulins |
5.7.1. Market Analysis, 2019-2023 and Forecast, 2024-2030, (Sales Value USD Million) |
5.7.2. Year-Over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) |
5.7.3. Market Opportunity Analysis |
5.8. Peptide Antibiotics |
5.8.1. Market Analysis, 2019-2023 and Forecast, 2024-2030, (Sales Value USD Million) |
5.8.2. Year-Over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) |
5.8.3. Market Opportunity Analysis |
5.9. Others |
5.9.1. Market Analysis, 2019-2023 and Forecast, 2024-2030, (Sales Value USD Million) |
5.9.2. Year-Over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) |
5.9.3. Market Opportunity Analysis |
6.Global Generic Injectables Market By Indication, 2019-2023 and Forecast 2024-2030 (Sales Value USD Million) |
6.1. Diabetes |
6.1.1. Market Analysis, 2019-2023 and Forecast, 2024-2030, (Sales Value USD Million) |
6.1.2. Year-Over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) |
6.1.3. Market Opportunity Analysis |
6.2. Cancer |
6.2.1. Market Analysis, 2019-2023 and Forecast, 2024-2030, (Sales Value USD Million) |
6.2.2. Year-Over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) |
6.2.3. Market Opportunity Analysis |
6.3. Cardiovascular Diseases |
6.3.1. Market Analysis, 2019-2023 and Forecast, 2024-2030, (Sales Value USD Million) |
6.3.2. Year-Over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) |
6.3.3. Market Opportunity Analysis |
6.4. Musculoskeletal |
6.4.1. Market Analysis, 2019-2023 and Forecast, 2024-2030, (Sales Value USD Million) |
6.4.2. Year-Over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) |
6.4.3. Market Opportunity Analysis |
6.5. CNS |
6.5.1. Market Analysis, 2019-2023 and Forecast, 2024-2030, (Sales Value USD Million) |
6.5.2. Year-Over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) |
6.5.3. Market Opportunity Analysis |
6.6. Infections |
6.6.1. Market Analysis, 2019-2023 and Forecast, 2024-2030, (Sales Value USD Million) |
6.6.2. Year-Over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) |
6.6.3. Market Opportunity Analysis |
6.7. Others |
6.7.1. Market Analysis, 2019-2023 and Forecast, 2024-2030, (Sales Value USD Million) |
6.7.2. Year-Over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) |
6.7.3. Market Opportunity Analysis |
7.Global Generic Injectables Market By Distribution Channel, 2019-2023 and Forecast 2024-2030 (Sales Value USD Million) |
7.1. Hospital Pharmacy |
7.1.1. Market Analysis, 2019-2023 and Forecast, 2024-2030, (Sales Value USD Million) |
7.1.2. Year-Over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) |
7.1.3. Market Opportunity Analysis |
7.2. Retail Pharmacy |
7.2.1. Market Analysis, 2019-2023 and Forecast, 2024-2030, (Sales Value USD Million) |
7.2.2. Year-Over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) |
7.2.3. Market Opportunity Analysis |
7.3. Drug Stores |
7.3.1. Market Analysis, 2019-2023 and Forecast, 2024-2030, (Sales Value USD Million) |
7.3.2. Year-Over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) |
7.3.3. Market Opportunity Analysis |
7.4. Online Prescription Stores |
7.4.1. Market Analysis, 2019-2023 and Forecast, 2024-2030, (Sales Value USD Million) |
7.4.2. Year-Over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) |
7.4.3. Market Opportunity Analysis |
8.Global Generic Injectables Market By Region, 2019-2023 and Forecast 2024-2030 (Sales Value USD Million) |
8.1. North America |
8.1.1. Market Analysis, 2019-2023 and Forecast, 2024-2030, (Sales Value USD Million) |
8.1.2. Year-Over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) |
8.1.3. Market Opportunity Analysis |
8.2. Europe |
8.2.1. Market Analysis, 2019-2023 and Forecast, 2024-2030, (Sales Value USD Million) |
8.2.2. Year-Over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) |
8.2.3. Market Opportunity Analysis |
8.3. Asia Pacific (APAC) |
8.3.1. Market Analysis, 2019-2023 and Forecast, 2024-2030, (Sales Value USD Million) |
8.3.2. Year-Over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) |
8.3.3. Market Opportunity Analysis |
8.4. Middle East and Africa (MEA) |
8.4.1. Market Analysis, 2019-2023 and Forecast, 2024-2030, (Sales Value USD Million) |
8.4.2. Year-Over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) |
8.4.3. Market Opportunity Analysis |
8.5. Latin America |
8.5.1. Market Analysis, 2019-2023 and Forecast, 2024-2030, (Sales Value USD Million) |
8.5.2. Year-Over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) |
8.5.3. Market Opportunity Analysis |
9.North America Generic Injectables Market 2019-2023 and Forecast 2024-2030 (Sales Value USD Million) |
9.1. Product Type Analysis 2019-2023 and Forecast 2024-2030 by Sales Value USD Million, Y-o-Y Growth (%), and Market Share (%) |
9.1.1.Monoclonal Antibodies |
9.1.2.Cytokines |
9.1.3.Insulin |
9.1.4.Vaccines |
9.1.5.Peptide Hormones |
9.1.6.Blood Factors |
9.1.7.Immunoglobulins |
9.1.8.Peptide Antibiotics |
9.1.9.Others |
9.2. Indication Analysis 2019-2023 and Forecast 2024-2030 by Sales Value USD Million, Y-o-Y Growth (%), and Market Share (%) |
9.2.1.Diabetes |
9.2.2.Cancer |
9.2.3.Cardiovascular Diseases |
9.2.4.Musculoskeletal |
9.2.5.CNS |
9.2.6.Infections |
9.2.7.Others |
9.3. Distribution Channel Analysis 2019-2023 and Forecast 2024-2030 by Sales Value USD Million, Y-o-Y Growth (%), and Market Share (%) |
9.3.1.Hospital Pharmacy |
9.3.2.Retail Pharmacy |
9.3.3.Drug Stores |
9.3.4.Online Prescription Stores |
9.4. Country Analysis 2019-2023 and Forecast 2024-2030 by Sales Value USD Million, Y-o-Y Growth (%), and Market Share (%) |
9.4.1.United States of America (USA) |
9.4.2.Canada |
10.Europe Generic Injectables Market 2019-2023 and Forecast 2024-2030 (Sales Value USD Million) |
10.1. Product Type Analysis and Forecast by Sales Value USD Million, Y-o-Y Growth (%), and Market Share (%) |
10.1.1.Monoclonal Antibodies |
10.1.2.Cytokines |
10.1.3.Insulin |
10.1.4.Vaccines |
10.1.5.Peptide Hormones |
10.1.6.Blood Factors |
10.1.7.Immunoglobulins |
10.1.8.Peptide Antibiotics |
10.1.9.Others |
10.2. Indication Analysis 2019-2023 and Forecast 2024-2030 by Sales Value USD Million, Y-o-Y Growth (%), and Market Share (%) |
10.2.1.Diabetes |
10.2.2.Cancer |
10.2.3.Cardiovascular Diseases |
10.2.4.Musculoskeletal |
10.2.5.CNS |
10.2.6.Infections |
10.2.7.Others |
10.3. Distribution Channel Analysis 2019-2023 and Forecast 2024-2030 by Sales Value USD Million, Y-o-Y Growth (%), and Market Share (%) |
10.3.1.Hospital Pharmacy |
10.3.2.Retail Pharmacy |
10.3.3.Drug Stores |
10.3.4.Online Prescription Stores |
10.4. Country Analysis 2019-2023 and Forecast 2024-2030 by Sales Value USD Million, Y-o-Y Growth (%), and Market Share (%) |
10.4.1.Germany |
10.4.2.France |
10.4.3.Italy |
10.4.4.United Kingdom (UK) |
10.4.5.Spain |
10.4.6.Rest of EU |
10.4.7. |
11.Asia Pacific (APAC) Generic Injectables Market 2019-2023 and Forecast 2024-2030 (Sales Value USD Million) |
11.1. Product Type Analysis and Forecast by Sales Value USD Million, Y-o-Y Growth (%), and Market Share (%) |
11.1.1.Monoclonal Antibodies |
11.1.2.Cytokines |
11.1.3.Insulin |
11.1.4.Vaccines |
11.1.5.Peptide Hormones |
11.1.6.Blood Factors |
11.1.7.Immunoglobulins |
11.1.8.Peptide Antibiotics |
11.1.9.Others |
11.2. Indication Analysis 2019-2023 and Forecast 2024-2030 by Sales Value USD Million, Y-o-Y Growth (%), and Market Share (%) |
11.2.1.Diabetes |
11.2.2.Cancer |
11.2.3.Cardiovascular Diseases |
11.2.4.Musculoskeletal |
11.2.5.CNS |
11.2.6.Infections |
11.2.7.Others |
11.3. Distribution Channel Analysis 2019-2023 and Forecast 2024-2030 by Sales Value USD Million, Y-o-Y Growth (%), and Market Share (%) |
11.3.1.Hospital Pharmacy |
11.3.2.Retail Pharmacy |
11.3.3.Drug Stores |
11.3.4.Online Prescription Stores |
11.4. Country Analysis 2019-2023 and Forecast 2024-2030 by Sales Value USD Million, Y-o-Y Growth (%), and Market Share (%) |
11.4.1.China |
11.4.2.India |
11.4.3.Australia and New Zealand (ANZ) |
11.4.4.Japan |
11.4.5.Rest of APAC |
12.Middle East and Africa (MEA) Generic Injectables Market 2019-2023 and Forecast 2024-2030 (Sales Value USD Million) |
12.1. Product Type Analysis and Forecast by Sales Value USD Million, Y-o-Y Growth (%), and Market Share (%) |
12.1.1.Monoclonal Antibodies |
12.1.2.Cytokines |
12.1.3.Insulin |
12.1.4.Vaccines |
12.1.5.Peptide Hormones |
12.1.6.Blood Factors |
12.1.7.Immunoglobulins |
12.1.8.Peptide Antibiotics |
12.1.9.Others |
12.2. Indication Analysis 2019-2023 and Forecast 2024-2030 by Sales Value USD Million, Y-o-Y Growth (%), and Market Share (%) |
12.2.1.Diabetes |
12.2.2.Cancer |
12.2.3.Cardiovascular Diseases |
12.2.4.Musculoskeletal |
12.2.5.CNS |
12.2.6.Infections |
12.2.7.Others |
12.3. Distribution Channel Analysis 2019-2023 and Forecast 2024-2030 by Sales Value USD Million, Y-o-Y Growth (%), and Market Share (%) |
12.3.1.Hospital Pharmacy |
12.3.2.Retail Pharmacy |
12.3.3.Drug Stores |
12.3.4.Online Prescription Stores |
12.4. Country Analysis 2019-2023 and Forecast 2024-2030 by Sales Value USD Million, Y-o-Y Growth (%), and Market Share (%) |
12.4.1.GCC Countries |
12.4.2.South Africa |
12.4.3.Rest of MEA |
13.Latin America Generic Injectables Market 2019-2023 and Forecast 2024-2030 (Sales Value USD Million) |
13.1. Product Type Analysis and Forecast by Sales Value USD Million, Y-o-Y Growth (%), and Market Share (%) |
13.1.1.Monoclonal Antibodies |
13.1.2.Cytokines |
13.1.3.Insulin |
13.1.4.Vaccines |
13.1.5.Peptide Hormones |
13.1.6.Blood Factors |
13.1.7.Immunoglobulins |
13.1.8.Peptide Antibiotics |
13.1.9.Others |
13.2. Indication Analysis 2019-2023 and Forecast 2024-2030 by Sales Value USD Million, Y-o-Y Growth (%), and Market Share (%) |
13.2.1.Diabetes |
13.2.2.Cancer |
13.2.3.Cardiovascular Diseases |
13.2.4.Musculoskeletal |
13.2.5.CNS |
13.2.6.Infections |
13.2.7.Others |
13.3. Distribution Channel Analysis 2019-2023 and Forecast 2024-2030 by Sales Value USD Million, Y-o-Y Growth (%), and Market Share (%) |
13.3.1.Hospital Pharmacy |
13.3.2.Retail Pharmacy |
13.3.3.Drug Stores |
13.3.4.Online Prescription Stores |
13.4. Country Analysis 2019-2023 and Forecast 2024-2030 by Sales Value USD Million, Y-o-Y Growth (%), and Market Share (%) |
13.4.1.Brazil |
13.4.2.Mexico |
13.4.3.Rest of LA |
14. Competition Landscape |
14.1. Market Player Profiles (Introduction, Brand/Product Sales, Financial Analysis, Product Offerings, Key Developments, Collaborations, M & A, Strategies, and SWOT Analysis) |
14.2.1.AstraZeneca |
14.2.2.Baxter International, Inc. |
14.2.3.Biocon |
14.2.4.Fresenius SE & Co. KGaA |
14.2.5.GlaxoSmithKline plc |
14.2.6.Hikma Pharmaceuticals plc |
14.2.7.Johnson & Johnson Services, Inc. |
14.2.8.Lupin Ltd. |
14.2.9.Merck KGaA |
14.2.10.Mylan N.V. |
14.2.11.Novartis AG (Sandoz International GmbH) |
14.2.12.Pfizer, Inc. |
15. Research Methodology |
16. Appendix and Abbreviations |
Key Market Players